Epistem Announces Evaluation of Genedrive® for Pathogen Detection
News Jan 16, 2014
Epistem Holdings Plc has announced that it has entered into a cooperative agreement with the US Air Force alongside an agreement with Johns Hopkins University (Advanced Physics Laboratory), to undertake the combat evaluation of Epistem's Genedrive® handheld molecular device for pathogen detection.
The agreement will commence immediately and provides $0.6m (GBP 0.4m) over 5 months to develop and evaluate Genedrive® for the identification of three known disease pathogens.
Successful completion of the combat evaluation programme will secure ongoing investment for the development of Genedrive® as a handheld pathogen detection unit for the US Department of Defence.
Preparations for the 2014 launch of the company's first Genedrive® disease test in Tuberculosis continue, with progress to resolve the earlier reported software and firmware issues now nearing completion.
Whilst unit testing is ongoing, preparations are being made for the commencement of final stage clinical trials in support of Indian regulatory approval.
2014 plans to undertake clinical trials with the Foundation for Innovative New Diagnostics (FIND) have also commenced as a forerunner to a potential WHO recommendation in 2015.
In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack. A study found that people who sleep fewer than 7 hours per night have lower blood levels of three physiological regulators, or microRNAs, which influence gene expression and play a key role in maintaining vascular health.